Table: Terumo -9-MTH group results (IFRS)
Feb 13 (Reuters)-
Terumo Corp
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
9 months ended 9 months ended Year to
Dec 31, 2025 Dec 31, 2024 Mar 31, 2026
LATEST YEAR-AGO COMPANY
RESULTS RESULT FORECAST
Sales 831.56 772.24 1.11 trln
(+7.7 pct) (+13.1 pct) (+6.9 pct)
Operating 144.87 133.50 181.50
(+8.5 pct) (+26.5 pct) (+15.1 pct)
Pretax 146.59 131.83
(+11.2 pct) (+24.7 pct)
Net 109.55 98.62 136.00
(+11.1 pct) (+23.4 pct) (+16.3 pct)
EPS Basic 74.27 yen 66.53 yen 92.20 yen
EPS Diluted 74.25 yen 66.51 yen
Ann Div 26.00 yen 30.00 yen
-Q2 Div 15.00 yen 13.00 yen
-Q4 Div 13.00 yen 15.00 yen
NOTE - Terumo Corp.
(Figures are reported based on international accounting rules (IFRS).)
If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half
dividend and Q4 to the second-half dividend announced before a new corporate law in
2006 allowed companies to pay and report dividends on a quarterly basis.
*Net - represents Net profit attributable to owners of the parent company.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4543.T
Recent news on Terumo
See all newsJapan's Nikkei slips for third day as global bond selloff, Mideast war weigh (updated)
Japan's Nikkei slips for third day as global bond selloff, Mideast war weigh
Table: Terumo -2025/26 group results (IFRS)
Table: Terumo -9-MTH group results (IFRS)
Brief: Terumo Launches Surtract™ Safety Syringe In The United States